<DOC>
	<DOC>NCT01083212</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656</brief_summary>
	<brief_title>To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>Patients with confirmed Type 2 diabetes mellitus for at least 1 year and treated with metformin. Body mass index between ≥19 and ≤42 kg/m2. Intake of another investigational drug within the last 30 days prior to enrolment. Clinically significant illness or clinically relevant trauma.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Gemfibrozil</keyword>
</DOC>